During the last three months, 24 analysts shared their evaluations of Travere Therapeutics TVTX, revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 13 | 10 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 7 | 5 | 0 | 0 | 0 |
| 2M Ago | 5 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Travere Therapeutics, revealing an average target of $22.17, a high estimate of $41.00, and a low estimate of $12.00. Surpassing the previous average price target of $18.09, the current average has increased by 22.55%.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Travere Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mohit Bansal | Wells Fargo | Raises | Overweight | $27.00 | $9.00 |
| Greg Harrison | Scotiabank | Announces | Sector Outperform | $23.00 | - |
| Joseph Schwartz | Leerink Partners | Raises | Outperform | $40.00 | $20.00 |
| Greg Harrison | B of A Securities | Raises | Buy | $20.00 | $18.00 |
| Vamil Divan | Guggenheim | Raises | Buy | $41.00 | $23.00 |
| Laura Chico | Wedbush | Raises | Outperform | $25.00 | $17.00 |
| Joseph Schwartz | Leerink Partners | Maintains | Outperform | $20.00 | $20.00 |
| Carter Gould | Barclays | Raises | Overweight | $18.00 | $14.00 |
| Edward Nash | Canaccord Genuity | Lowers | Buy | $22.00 | $23.00 |
| Carly Kenselaar | Citigroup | Lowers | Buy | $19.00 | $23.00 |
| Vamil Divan | Guggenheim | Lowers | Buy | $23.00 | $25.00 |
| Greg Harrison | B of A Securities | Lowers | Buy | $18.00 | $19.00 |
| Ed Arce | HC Wainwright & Co. | Lowers | Buy | $18.00 | $23.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $23.00 | $20.00 |
| Edward Nash | Canaccord Genuity | Raises | Buy | $23.00 | $18.00 |
| Vamil Divan | Guggenheim | Announces | Buy | $25.00 | - |
| Carly Kenselaar | Citigroup | Raises | Buy | $23.00 | $14.00 |
| Greg Harrison | B of A Securities | Raises | Buy | $19.00 | $18.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $23.00 | $20.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $20.00 | $19.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $20.00 | $19.00 |
| Carter Gould | Barclays | Raises | Overweight | $14.00 | $12.00 |
| Allison Bratzel | Piper Sandler | Raises | Neutral | $12.00 | $11.00 |
| Laura Chico | Wedbush | Raises | Outperform | $16.00 | $13.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travere Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Travere Therapeutics compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into Travere Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Travere Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Travere Therapeutics Better
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Travere Therapeutics's Economic Impact: An Analysis
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Travere Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 68.08%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Travere Therapeutics's net margin excels beyond industry benchmarks, reaching -130.11%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -157.84%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Travere Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -11.59%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Travere Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 26.62, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
